找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Mesothelioma; From Research to Cli Giovanni Luca Ceresoli,Emilio Bombardieri,Maurizio Book 2019 Springer Nature Switzerland AG 2019 Lung tu

[复制链接]
楼主: 出租
发表于 2025-3-25 05:43:20 | 显示全部楼层
发表于 2025-3-25 09:57:16 | 显示全部楼层
发表于 2025-3-25 13:26:47 | 显示全部楼层
发表于 2025-3-25 17:43:35 | 显示全部楼层
Genetics and Epigenetics of Mesothelioma,ents. These patients are more sensitive to asbestos exposure than those who do not carry such mutations and may benefit of specific treatments. Additionally, epigenetic mechanisms, such as methylation or miRNA alterations, may modify gene expression and drive carcinogenesis. The same abnormalities m
发表于 2025-3-25 22:23:44 | 显示全部楼层
发表于 2025-3-26 02:49:07 | 显示全部楼层
Pathological Diagnosis of Mesothelioma, between benign and malignant mesothelial proliferations..This chapter is an update of the morphological, immunohistochemical, and molecular features, with particular regard to diffuse malignant mesothelioma diagnosis.
发表于 2025-3-26 04:24:54 | 显示全部楼层
发表于 2025-3-26 10:47:03 | 显示全部楼层
Role of Metabolic Imaging in Mesothelioma,characterized by the worst prognosis. PET-CT is gradually becoming essential in assessment of tumour response in patients undergoing chemotherapy. Metabolic imaging analysis permits the early identification of non-responders to chemotherapy, avoiding unsuccessful treatment, characterized by importan
发表于 2025-3-26 15:49:12 | 显示全部楼层
Surgery and Multimodality Treatment in Malignant Pleural Mesothelioma,ideration..Individualization of care for each patient is mandatory in choosing the most appropriate treatment to minimize the complications and to maximize the benefits..The aim of this chapter is to give an overview on the current state of multimodality treatment in MPM.
发表于 2025-3-26 20:34:11 | 显示全部楼层
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma,cond-line setting, if clinical trials are not available, single-agent therapy with vinorelbine or gemcitabine may be considered. Alternatively, patients achieving a prolonged benefit from first-line pemetrexed-platinum treatment may be candidate to rechallenge with pemetrexed-based regimens.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-19 14:20
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表